News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Mynet Finans Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Lynwood Opportunities Master Fund, Lynwood Capital Management Inc., and Ben Shapiro have reported a beneficial ownership of 4.6% in Kazia Therapeutics (KZIA) through American Depositary Shares as of June 30, 2026. This stake represents 264,980,500 Ordinary Shares, with each ADS equivalent to 500 Ordinary …
Canaccord Genuity has initiated coverage on Kazia Therapeutics (KZIA) with a 'Buy' rating and a price target of $29.00, significantly higher than its current market price of $13.09. Despite this positive analyst outlook and strong momentum, the company holds a low GF Score™ of …
This article first appeared on GuruFocus. Release Date: August 07, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Physical store sales grew 9.7% same-store sales, with strong performance across categories including white goods …
BTIG has reiterated its Buy rating for Kazia Therapeutics (KZIA.US) and maintained its price target at $34. This indicates continued confidence from the analyst firm in the company's prospects.
This article provides a detailed balance sheet for Kazia Therapeutics Ltd (KZIA), presenting quarterly and annual financial data spanning several years. It includes key financial metrics such as cash and short-term investments, total assets, current liabilities, and shareholders' equity, along with year-over-year percentage changes. …
This article provides a technical analysis of Kazia Therapeutics Ltd (KZIA), detailing various technical indicators and moving averages. It offers insights into the stock's current technical status, including buy, sell, and neutral signals from indicators like MACD, RSI, and moving averages. The analysis is …
Kazia Therapeutics has filed a provisional patent application for a new perioperative therapeutic strategy aimed at preventing metastatic recurrence in high-risk early-stage triple-negative breast cancer (TNBC). The strategy, supported by strong preclinical data and translational studies, involves adjuvant paxalisib which showed significant reductions in …
The article provides an overview of Kazia Therapeutics Ltd (KZIA) with a focus on its institutional confidence, detailing significant shareholders and their activity. Key shareholders include Chernett (Jorey) with a substantial increase in shares held, alongside other investment groups like Alyeska Investment Group and …
Kazia Therapeutics Ltd is an oncology-focused drug development company specializing in treatments for brain, renal, and liver cancers. Their lead program, paxalisib, is an investigational PI3K/Akt/mTOR pathway inhibitor for brain cancer, and they are also developing EVT801 for new blood vessel and lymphatic vessel …
This article provides a detailed cash flow statement for Kazia Therapeutics Ltd (KZIA), presenting both annual and quarterly data across operating, investing, and financing activities. It includes historical financial figures, percentage changes year-over-year, and explanations of key cash flow metrics like operating, investing, and …
This article provides a detailed breakdown of Kazia Therapeutics Ltd (KZIA) shareholder structure, including major individual and institutional holdings. It lists key shareholders like Jorey Chernett and Alyeska Investment Group, along with data on institutional shareholding trends over recent quarters. The report also categorizes …
This article provides an overview of Kazia Therapeutics Ltd (KZIA)'s dividend history and stock split events. It states that no dividends have been distributed in the past five years and lists several upcoming merger-related stock splits with varying ratios in late 2024 and early …
This article provides an analysis of Kazia Therapeutics Ltd's (KZIA) revenue breakdown by business segments, regional revenue, and profit contribution. The data indicates that relevant financial information for FY2021 and FY2022 has not been disclosed by the company. Consequently, there is no available revenue …
This article provides a detailed risk assessment for Kazia Therapeutics Ltd (KZIA), focusing on volatility, financial risk, and investment risk metrics. It presents various financial indicators such as Beta, VaR, maximum drawdown, realized volatility, and liquidity metrics over different timeframes. The data shows significant …
Search by ticker symbol or company name and select a result to open its chart.